Free Trial

111 Q2 2024 Earnings Report

111 logo
$0.43 0.00 (-0.70%)
As of 01/17/2025 04:00 PM Eastern

111 EPS Results

Actual EPS
-$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

111 Revenue Results

Actual Revenue
$471.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

111 Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

111 Earnings Headlines

111 (NASDAQ:YI) Receives Sell (E+) Rating from Weiss Ratings
111 Stock Set to Reverse Split on Friday, January 24th (NASDAQ:YI)
Tesla Shares Soar After Trump Win (Act Now)
Are you ready to see why Tesla might be the biggest opportunity on the market today? Right now, Tesla stock is at a critical juncture, and Lance believes it’s primed for explosive growth. That’s why he’s giving away his eBook, The Bullish Case for Tesla, for FREE—but only for a limited time.
111, Inc. Announces ADS Ratio Change
See More 111 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 111? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 111 and other key companies, straight to your email.

About 111

111 (NASDAQ:YI) engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

View 111 Profile

More Earnings Resources from MarketBeat